Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 20Lymphoid 16Myeloid 7CNS 5Sarcoma 2Classical hematology 2Thoracic 1Other solid neoplasm 1

Conditions

Rhabdomyosarcoma 2Sarcoma 1Malignant mesenchymal tumor 1

Interventions

Specimen Handling 38Magnetic Resonance Spectroscopy 32Cyclophosphamide 27Doxorubicin 24Temozolomide 23Biopsy 23pembrolizumab 22Radiotherapy 19X-Rays 18Radiation 18Nivolumab 16Vincristine 14Irinotecan 13Phantoms, Imaging 12Ifosfamide 12Gemcitabine 11fludarabine 10cabozantinib 10atezolizumab 10Ipilimumab 10Bevacizumab 9liposomal doxorubicin 8Paclitaxel 8Immunoglobulin G 8Surgical Procedures, Operative 7Dactinomycin 7Carboplatin 7palbociclib 6olaparib 6durvalumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Filgrastim × Sarcoma × 90 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

NCT01871766 2026-04-24

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
115 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡